Filtered By:
Source: Cardiovascular Toxicology
Condition: Heart Failure
Education: Study
Therapy: Thrombolytic Therapy

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 1 results found since Jan 2013.

Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Abstract Poly(ADP-ribosyl)ation is an immediate cellular repair response to DNA damage and is catalyzed primarily by poly(ADP-ribose)polymerase-1 (PARP1), which is the most abundant of the 18 different PARP isoforms and accounts for more than 90% of the catalytic activity of PARP in the cell nucleus. Upon detection of a DNA strand break, PARP1 binds to the DNA, cleaves nicotinamide adenine dinucleotide between nicotinamide and ribose and then modifies the DNA nuclear acceptor proteins by formation of a bond between the protein and the ADP-ribose residue. This generates ribosyl-ribosyl linkages that act as a signal...
Source: Cardiovascular Toxicology - July 2, 2018 Category: Cardiology Authors: Henning RJ, Bourgeois M, Harbison RD Tags: Cardiovasc Toxicol Source Type: research